Leveraging our clinically-validated masking technology and capabilities to advance a pipeline of differentiated masked I-O therapies for validated targets

Our tumor-selective I-O therapies are designed to unlock the potential for durable efficacy by focusing anti-tumor activity within the tumor microenvironment without severe side effects associated with systemically active I-O agents.